ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ZURA
PROK (35) TECX (30) TRXB (48) AUTL (21) ⌘ Pro Terminal →

Zura Bio Limited (Class A) (ZURA) — RQD Stock Rating Cockpit

$4.04 +4.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.07

Zura Bio Limited (Class A) (ZURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $389.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZURA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ZURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Zura Bio Limited (Class A) (NASDAQ: ZURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.04 (+4.93% 1D, market cap $389.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ZURA ranks #829 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ZURA compare to PROK and TECX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ZURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $391.6M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, ZURA leads on earnings multiple (N/A) while ZURA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZURA?
▼

Per ZURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855644), Zura Bio Limited (Class A) generated $210.7M in revenue (+36.3% YoY), -$68.7M in net income, and -$64.9M in free cash flow against $113.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.07 (+0.70%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (5)Whales (5)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
$8 Bull$4 Base$3 Bear
📬 FREE ZURA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZURA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY ZURA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (21% of score)

FRED Regime × Technicals: 19% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$4.23-5.4% Next Q
Q2 (-2Q)
34
Grade E$4.00+6.7% Next Q
Q3 (-1Q)
32
Grade E$4.27-5.4% Next Q
Current
29
Grade E$4.04-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.58) and Max Pain ($4.24) forces dealer call-delta covering toward $7.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE19% OF RANGE
L: $3$4.04H: $7
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ZURA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 42.0% gross margin and -17.51% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

8/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ZURA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZURA)

  • ✓Walkthrough of ZURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ZURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -24.06%📐 HORIZONTAL RANGE
2026-11-03O $3.85H $4.04L $3.85C $4.04VOL 4.08M
RES: $8.48SUP: $3.12SMA50: $4.58SMA200: $5.23
$7.33$6.22$5.12$4.01$2.91RES $8.48SUP $3.12$4.042026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZURA Butterfly Map → + Track ZURA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +36.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ZURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZURA)

Health Care Rank #829 of 1015 ⚔️ PROK vs ZURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZURA vs. PROK, TECX, TRXB, AUTL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Zura Bio Limited (Class A) (ZURA) ranks #829 by composite RQD confidence (29/100, grade E) and #477 by equity capitalization ($389.2M). Within this direct 5-issuer industry benchmark cohort, ZURA leads on earnings valuation at N/A trailing P/E, while ZURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with ZURA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZURA ACTIVE
Zura Bio Limited (Class A)
E 29/100 — — -35.0% +4.93% $389.2M Benchmark Subject
PROK
ProKidney Corp. (Class A)
D- 35/100 — — -35.0% -11.90% $391.6M /prok-vs-zura →
TECX
Tectonic Therapeutic Inc.
E 30/100 — — -35.0% -3.51% $386.7M /tecx-vs-zura →
TRXB
TRex Bio Inc.
D 48/100 — — — +1.63% $377.1M /trxb-vs-zura →
AUTL
Autolus Therapeutics plc
E 21/100 — -27.8% -35.0% -3.80% $404.6M /autl-vs-zura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001855644 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zura Bio Limited (Class A) (ZURA) reported GAAP revenue of $210.7M (+36.3% vs. FY2024 revenue of $154.5M , and +20.1% cumulative change since FY2023) , GAAP net income of -$68.7M, operating cash flow of -$64.8M, and free cash flow of -$64.9M (-130.6% YoY). On the balance sheet, ZURA closed FY2025 with $113.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $210.7M -$68.7M -$64.8M -$64.9M $113.9M —
FY2024 (FY) 2024-12-31 $154.5M -$52.4M -$28.1M -$28.2M $179.5M —
FY2023 (FY) 2023-12-31 $175.4M -$60.4M -$15.1M -$15.1M — —

3. ZURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Zura Bio Limited (Class A) (NASDAQ: ZURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $4.04 (+4.93% 1D, market cap $389.2M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ZURA ranks #829 in composite RQD confidence.

How does ZURA compare to PROK and TECX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ZURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $391.6M) and TECX (Tectonic Therapeutic Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $386.7M). Among the 5-stock peer group, ZURA leads on earnings multiple (N/A) while ZURA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZURA?

Per ZURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001855644), Zura Bio Limited (Class A) generated $210.7M in revenue (+36.3% YoY), -$68.7M in net income, and -$64.9M in free cash flow against $113.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZURA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZURA last traded at $4.04 (+4.93% on volume of 4,078,533 shares), positioning the stock -11.79% below its 50-day simple moving average ($4.58) and -22.75% below its 200-day simple moving average ($5.23). Across its 52-week range of $3.25 to $7.44, ZURA sits at the 18.9% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.53 to $4.55).

Direct Sub-Reports: ZURA RQD Cockpit ZURA 12M Forecast ZURA Earnings & Move ZURA Dividends & DRIP ZURA Insiders & 13F ZURA Whale Options ZURA Profit Sankey ZURA News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

ZURA — Zura Bio Limited (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Zura Bio Limited (Class A) (ZURA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.04 (+4.93% 1D, market capitalization $389.2M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -17.51%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Zura Bio Limited (Class A) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances)..4B. Reported revenue is — in each of the listed fiscal years. — for product lines, customer base, or revenue model detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Zura Bio Limited (Class A) (ZURA) reported $210.7M in annual revenue (up from $154.5M in FY2024, +36.3% YoY) and -$68.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($175.4M revenue, -$60.4M net income) through FY2025, ZURA scaled operating cash flow to -$64.8M and free cash flow to -$64.9M, backed by $113.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -17.51% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $3.25 – $7.44 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ZURA carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ZURA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $210.7M and free cash flow of -$64.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ZURA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ZURA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Zura Bio Limited (Class A) (ZURA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ZURA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ZURA Bull vs. Bear Conversation Board — What's Your Call at $4.04?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ZURA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ZURA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $5.33 (+31.9%)
📌 Pinned Debate

The balance sheet scores 10/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash of $109.4M remains above zero.

Long ZURA at $4.04 targeting $5.33. The balance sheet scores 10/20 with an Altman Z-Score of 2.5 and Debt/Equity of 0.5, and reported cash of $109.4M remains above zero.. Institutional whale score is 5/20 and the risk/reward vs. the $3.25 52-week low is skewed heavily in favor of bulls.

EarningsSniper 🐂 BULL

@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $4.04 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $3.07 (-24.0%)
Spot @ $4.04

The company reports zero revenue, a -35% ROIC, a -17.51% FCF yield, and an RQD verdict of Strong Sell with an RQD score of 29.

Sitting on the sidelines or leaning short ZURA above $4.04. The company reports zero revenue, a -35% ROIC, a -17.51% FCF yield, and an RQD verdict of Strong Sell with an RQD score of 29.. Until Fundamental Cash Engine (5/20) and FCF yield (-17.51%) inflect higher, upside is capped near $7.44.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%